Sign in →

Test Code GAL3 Galectin-3, Serum

Reporting Name

Galectin-3, S

Useful For

An aid in prognosis for patients diagnosed with heart failure


Risk-stratification of heart failure patients


An early indication of treatment failure and as a therapeutic target

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Serum Red

Specimen Required

Collection Container/Tube: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Specimen Minimum Volume

0.2 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Frozen (preferred) 365 days
  Refrigerated  24 hours

Reference Values

<24 months: not established

2-17 years: ≤25.0 ng/mL

≥18 years: ≤22.1 ng/mL

Day(s) and Time(s) Performed

Monday; 9 a.m.

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
GAL3 Galectin-3, S 62419-7


Result ID Test Result Name Result LOINC Value
86202 Galectin-3, S 62419-7

Clinical Information

Heart failure is a complex cardiovascular disorder with a variety of etiologies and heterogeneity with respect to the clinical presentation of the patient. Heart failure is significantly increasing in prevalence with an aging population and is associated with high short- and long-term mortality rate. Over 80% of patients diagnosed and treated for acute heart failure syndromes in the emergency department are readmitted within the forthcoming year, incurring costly treatments and therapies.(1)


The development and progression of heart failure is a clinically silent process until manifestation of the disorder, which typically occurs late and irreversibly into its progression. Mechanistically, heart failure, whether due to systolic or diastolic dysfunction, is thought to progress primarily through adverse cardiac remodeling and fibrosis in response to cardiac injury and/or stress. Galectin-3 is a biomarker that appears to be actively involved in both the inflammatory and fibrotic pathways that are thought to be involved.


Galectin-3 is a carbohydrate-binding lectin whose expression is associated with inflammatory cells including macrophages, neutrophils, and mast cells. Galectin-3 has been linked to cardiovascular physiological processes including myofibroblast proliferation, tissue repair, and cardiac remodeling in the setting of heart failure. Concentrations of galectin-3 have been used to predict adverse remodeling after a variety of cardiac insults.

Analytic Time

1 day

NY State Approved


Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)


If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen (